Literature DB >> 22269820

Comparative study on the pharmacodynamics of cisatracurium: continuous infusion or intermittent bolus injection.

You-jing Dong1, Xu Li.   

Abstract

OBJECTIVE: To explore a better administration way through comparison of the pharmacodynamics of cisatracurium administered by continuous infusion or intermittent bolus injection.
METHODS: Thirty patients (ASAI-II) who had no neuromuscular disease and underwent selective surgery under general anesthesia were randomly divided into group I and II (each group with 15 patients). In group I, patients received cisatracurium by continuous infusion and in group II, by intermittent bolus injection. The responses of adductor pollicis to train-of-four (TOF) stimulation were monitored. The duration of neuromuscular blockade, recovery index and total dose of cisatracurium consumption were recorded in the two groups. Intravenous anesthesia was used for anesthesia induction and sevoflurane inhalation for maintenance of anesthesia.
RESULTS: The mean infusion rate was significantly lower in group I (0.78 ± 0.15 μg.kg(-1).min(-1)) than in group II (1.09 ± 0.33 μg.kg(-1).min(-1)) (P<0.05). There was no significant difference in duration of neuromuscular blockade between the two groups (P>0.05). The recovery index was 13.13 ± 3.36 min in group I and 14.38 ± 4.48 min in group II, which indicated that the recovery was faster in group I than in group II, but without statistical significance (P>0.05). During the duration of neuromuscular blockade, 8 patients had T(1)<3%, 4 T(1) of 3%-7% and 3 T(1) of 7%-10% in group I; T(1) was maintained between 0 and 20% in group II.
CONCLUSIONS: Although cisatracurium consumption was significantly lower in continuous infusion than in intermittent bolus injection, continuous infusion can obtain more stable neuromuscular blockade than intermittent bolus injection.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22269820     DOI: 10.1016/j.cct.2012.01.002

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  3 in total

1.  Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study.

Authors:  Nesrine Fraj; Khaoula Meddeb; Abdelbaki Azouzi; Sana Romdhani; Helmi Ben Saad; Mohamed Boussarsar
Journal:  Pan Afr Med J       Date:  2020-12-15

2.  The Real-Time and Patient-Specific Prediction for Duration and Recovery Profile of Cisatracurium Based on Deep Learning Models.

Authors:  Kan Wang; Binyu Gao; Heqi Liu; Hui Chen; Honglei Liu
Journal:  Front Pharmacol       Date:  2022-02-04       Impact factor: 5.810

3.  Comparative Analysis of the Anesthesia Effect of Cisatracurium Besylate and Mivacurium Chloride Otolaryngology Surgery.

Authors:  Shibin Huang; Qi Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-18       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.